

IN THE CLAIMS:

Please cancel Claims: 1-20.

Please amend the following claims:

21. (amended) A method of treating B-cell lymphoma, comprising:

a) providing:

i) a subject having a B-cell lymphoma; and

ii) a multivalent vaccine comprising at least two recombinant heavy chain variable regions of immunoglobulin molecules derived from said subjects's B-cell lymphoma cells, wherein said at least two recombinant heavy chain variable regions differ by at least one idiotope; and

b) administering said multivalent vaccine to said subject.

22. (amended) The method of Claim 21, wherein said vaccine comprises at least two recombinant immunoglobulin molecules comprising said recombinant heavy chain variable regions derived from said lymphoma cells.

23. (amended) The method of Claim 23, wherein said adjuvant is Syntex adjuvant.

Please add the following new claims:

25. (new) The method of Claim 21, wherein at least one of said at least two recombinant heavy chain variable regions is conjugated to a carrier protein.

26. (new) The method of Claim 25, wherein said carrier protein is KLH.

27. (new) A method of treating B-cell lymphoma, comprising:
- a) providing:
 - i) a subject having a B-cell lymphoma; and
 - ii) a multivalent [vaccine] comprising at least two recombinant light chain variable regions of immunoglobulin molecules derived from said subjects' B-cell lymphoma cells, wherein said at least two recombinant light chain variable regions differ by at least one idiotope; and
 - b) administering said multivalent vaccine to said subject.
28. (new) The method of Claim 27, wherein said vaccine comprises at least two recombinant immunoglobulin molecules comprising said recombinant light chain variable regions derived from said lymphoma cells.
29. (new) The method of Claim 27, wherein said vaccine further comprises an adjuvant.
30. (new) The method of Claim 28, wherein said adjuvant is Syntex adjuvant.
31. (new) The method of Claim 27, wherein at least one of said at least two recombinant light chain variable regions is conjugated to a carrier protein.
32. (new) The method of Claim 31, wherein said carrier protein is KLH.

REMARKS

Claims 1-24 were originally filed in the grandparent case. In an Office Action dated September 3, 1997, the Examiner restricted the claims into three Groups, with Group I containing Claims 1-6, Group II containing Claims 7-20, and Group III containing Claims 21-24. In a Response dated January 8, 1998, Applicant elected, without traverse, to prosecute